Mayne Pharma Group Limited (MAYNF) Q4 2026 Earnings Call Transcript

SA Transcripts 162.03K Followers Follow Mayne Pharma Group Limited ( MAYNF ) Q4 2026 Earnings Call August 26, 2026 7:30 PM EDT Company Participants Aaron Gray - Chief Executive Officer Griffin Buchanan - Chief Financial Officer Thomas Duthy - Manager of Investor Relations Conference Call Participants Andrew Goodsall - MST Financial Services Pty Limited, Research Division Presentation Operator Thank you for standing by, and welcome to the Mayne Pharma Group Limited Full Year 2026 Results. [Operator Instructions] I'd now like to hand the conference over to Mr. Aaron Gray, CEO. Please go ahead. Aaron Gray Chief Executive Officer Thank you, operator. Good morning, everyone, and thank you for joining Mayne Pharma's fiscal year '26 Full Year Results Presentation. I'm Aaron Gray, Chief Executive Officer, and I'm joined today by Griffin Buchanan, our Chief Financial Officer, who was appointed in August. Today, I'll begin with our fiscal '26 corporate highlights and global footprint. Griffin will then take you through the group financial performance before I return to walk through each of the three segments: women's health, dermatology and DistributeRx, and international. And we'll then close with our future growth drivers and fiscal year '27 focus and outlook. Then we will open the line for questions. Please take a moment to read the disclaimer regarding forward-looking statements and the use of non-IFRS measures. Today's comments should be read in conjunction with our audited financial statements and ASX disclosures. Turning to Slide 3 and our fiscal year '26 corporate highlights. Fiscal year ' 26 was a year of resilience and focus against the backdrop of considerable distraction and disruption. First, as part of our realignment of the women's health sales force, we refreshed our sales and marketing materials to better support the team in the field. We also introduced dedicated menopause and contraception field representation, which will allow us to drive